In patients with diabetes, fibroblasts may aggregate at sites of corneal injury, potentially promoting scar hyperplasia and reducing corneal transparency. These changes may be reversed by PDGFRβ phosphorylation inhibitors, suggesting new therapeutic avenues.
Zheng et al. (Wed,) studied this question.